My Treatment Approach: Metastatic Castration-Resistant Prostate Cancer : Episode 9

Video

May 8, 2023

Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

Author(s):

Andrew J. Armstrong, MD,Matthew Manning, MD

Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.

EP: 1.The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP: 2.Approved Treatment Options for Patients with mCRPC

EP: 3.Patient Profile: A 78-Year-Old Man with mCRPC

EP: 4.Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy

EP: 5.Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases

EP: 6.Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC

EP: 7.Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

EP: 8.Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

Now Viewing

EP: 9.Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

EP: 10.Closing Thoughts on the Future of mCRPC Treatment

Related Content

December 11th 2024

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer

July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

December 5th 2024

FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer

June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Capivasertib Plus Abiraterone/ADT in PTEN-Deficient mHSPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 25th 2024

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer